Nicotinic modulation of attentional deficits in schizophrenia

Latent Inhibition: Cognition, Neuroscience and Applications to Schizophrenia

Volumn 9780521517331, Issue , 2010, Pages 477-499

  Schnur, Paul ^a   Hoffman, Allison Chausmer ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926129565     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511730184.021     Document Type: Chapter

References (137)

1. Acri, J. B., Morse, D. E., Popke, E. J., & Grunberg, N. E. (1994). Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats. Psychopharmacology (Berl.), 114, 369-374.
2. Adler, L. E., Hoffer, L. D., Wiser, A., & Freedman, R. (1993). Normalization of auditory physiology by cigarette smoking in schizophrenic patients. American Journal of Psychiatry, 150, 1856-1861.
3. Adler, L. E., Hoffer, L. J., Griffith, J., Waldo, M. C., & Freedman, R. (1992). Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biological Psychiatry, 32, 607-616.
4. AhnAllen, C. G., Nestor, P. G., Shenton, M. E., McCarley, R. W., & Niznikiewicz, M. A. (2008). Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia. Schizophrenia Research, 100, 261-269.
5. Allan, L. M., Williams, J. H., Wellman, N. A., et al. (1995). Effects of tobacco smoking, schizotypy and number of pre-exposures on latent inhibition in healthy subjects. Personality and Individual Differences, 19, 893-902.
6. Alves, C. R., Delucia, R., & Silva, M. T. (2002). Effects of fencamfamine on latent inhibition. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 26, 1089-1093.
7. Anfang, M. K., & Pope, H. G., Jr. (1997). Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacology (Berl.), 134, 153-156.
8. Anthony, B. (1990). Blink modulation in attention-deficit disorder. Psychophysiology, 27, S6.
9. Aston-Jones, G., & Kalivas, P.W. (2008). Brain norepinephrine rediscovered in addiction research. Biological Psychiatry, 63, 1005-1006.
10. Azizian, A., Monterossa, J. R., Brody, A. L., Simon, S. L., & London, E. D. (2008). Severity of nicotine dependence moderates performance on perceptual motor tests of attention. Nicotine & Tobacco Research, 10, 599-606.
11. Barr, R. S., Culhane, M. A., Jubelt, L. E., et al. (2008). The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology, 33, 480-490.
12. Baschnagel, J. S., & Hawk, L. W. (2008). The effects of nicotine on the attentional modification of the acoustic startle response in nonsmokers. Psychopharmacology (Berl.), 198, 93-101.
13. Berns, G. S., McClure, S. M., Pagnoni, G., & Montague, P. R. (2001). Predictability modulates human brain response to reward. Journal of Neuroscience, 21, 2793-2798.
14. Berridge, K. C. (2007). The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl.), 191, 391-431.
15. Berridge, K. C., & Robinson, T. E. (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Research Reviews, 28, 309-369.
16. Berridge, K. C., & Robinson, T. E. (2003). Parsing reward. Trends in Neuroscience, 26, 507-513.
17. Bethus, I., Muscat, R., & Goodall, G. (2006). Dopamine manipulations limited to preexposure are sufficient to modulate latent inhibition. Behavioral Neuroscience, 120, 554-562.
18. Bierut, L. J., Stitzel, J. A., Wang, J. C., et al. (2008). Variants in nicotinic receptors and risk for nicotine dependence. American Journal of Psychiatry, 165, 1163-1171.
19. Boulter, J., Connolly, J., Deneris, E., et al. (1987). Functional expression of two neuronal nicotinic acetylcholine receptors from cDNA clones identifies a gene family. Proceedings of the National Academy of Sciences of the United States of America, 84, 7763-7767.
20. Boulter, J., O'Shea-Greenfield, A., Duvoisin, R.M., et al. (1990). Alpha 3, alpha 5, and beta 4: three members of the rat neuronal nicotinic acetylcholine receptor-related gene family form a gene cluster. Journal of Biological Chemistry, 265, 4472-4482.
21. Braff, D. L., Grillon, C., & Geyer, M. A. (1992). Gating and habituation of the startle reflex in schizophrenic patients. Archives of General Psychiatry, 49, 206-215.
22. Breese, C. R., Lee, M. J., Adams, C. E., et al. (2000). Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology, 23, 351-364.
23. Brody, A. L., Mandelkern, M. A., London, E. D., et al. (2006). Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Archives of General Psychiatry, 63, 907-915.
24. Buhusi, C. V., Gray, J. A., & Schmajuk, N. A. (1998). Perplexing effects of hippocampal lesions on latent inhibition: A neural network solution. Behavioral Neuroscience, 112, 316-351.
25. Bushnell, P. J., Oshiro, W. M., & Padnos, B. K. (1997). Detection of visual signals by rats: effects of chlordiazepoxide and cholinergic and adrenergic drugs on sustained attention. Psychopharmacology (Berl.), 134, 230-241.
26. Chang, T., Meyer, U., Feldon, J., & Yee, B. K. (2007). Disruption of the US pre-exposure effect and latent inhibition in two-way active avoidance by systemic amphetamine in C57BL/6 mice. Psychopharmacology (Berl.), 191, 211-221.
27. Changeux, J. P., & Edelstein, S. J. (2005). Allosteric mechanisms of signal transduction. Science, 308, 1424-1428.
28. Chausmer, A. L., Smith, B. J., Kelly, R. Y., & Griffiths, R. R. (2003). Cocaine-like subjective effects of nicotine are not blocked by the D1 selective antagonist ecopipam (SCH 39166). Behavioural Pharmacology, 14, 111-120.
29. Corrigall, W. A., & Coen, K. M. (1989). Fixed-interval schedules for drug self-administration in the rat. Psychopharmacology (Berl.), 99, 136-139.
30. Day, M., Pan, J. B., Buckley, M. J., et al. (2007). Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochemical Pharmacology, 73, 1123-1134.
31. Della Casa, V., Hofer, I., & Feldon, J. (1999). Latent inhibition in smokers vs. nonsmokers: Interaction with number or intensity of preexposures? Pharmacology, Biochemistry and Behavior, 62, 353-359.
32. Deneris, E. S., Connolly, J., Boulter, J., et al. (1988). Primary structure and expression of beta 2: a novel subunit of neuronal nicotinic acetylcholine receptors. Neuron, 1, 45-54.
33. Di Chiara, G. (2000). Role of dopamine in the behavioural actions of nicotine related to addiction. European Journal of Pharmacology, 393, 295-314.
34. Dolan, R. J., Fletcher, P., Frith, C. D., et al. (1995). Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature, 378, 180-182.
35. Dunn, L. A., Atwater, G. E., & Kilts, C. D. (1993). Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action. Psychopharmacology (Berl.), 112, 315-323.
36. Durany, N., Zöchling, R., Boissl, K. W., et al. (2000). Human post-mortem striatal a4b2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neuroscience Letters, 287, 109-112.
37. Evans, L. H., Gray, N. S., & Snowden, R. J. (2007). A new continuous withinparticipants latent inhibition task: examining associations with schizotypy dimensions, smoking status and gender. Biological Psychology, 74, 365-373.
38. Feldon, J., & Weiner, I. (1991). Effects of haloperidol on the multitrial partial reinforcement extinction effect (PREE): evidence for neuroleptic drug action on nonreinforcement but not on reinforcement. Psychopharmacology (Berl.), 105, 407-414.
39. Freedman, R., Adams, C. E., & Leonard, S. (2000). The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. Journal of Chemical Neuroanatomy, 20, 299-306.
40. Freedman, R., Coon, H., Myles-Worsley, M., et al. (1997). Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proceedings of the National Academy of Sciences of the United States of America, 94, 587-592.
41. Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biological Psychiatry, 38, 22-33.
42. Gal, G., Mendlovic, S., Bloch, Y., et al. (2005). Learned irrelevance is disrupted in first-episode but not chronic schizophrenia patients. Behavioural Brain Research, 159, 267-275.
43. Gilbert, D. G., Sugai, C., Zuo, Y., et al. (2007). Brain indices of nicotine's effects on attentional bias to smoking and emotional pictures and to task-relevant targets. Nicotine & Tobacco Research, 9, 351-363.
44. Goff, D. C., Sullivan, L. M., McEvoy, J. P., et al. (2005). A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research, 80, 45-53.
45. Goldberg, S. R., Spealman, R. D., & Goldberg, D. M. (1981). Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science, 214, 573-575.
46. Gould, T. J., Collins, A. C., & Wehner, J. M. (2001). Nicotine enhances latent inhibition and ameliorates ethanol-induced deficits in latent inhibition. Nicotine & Tobacco Research, 3, 17-24.
47. Gould, T. J., & Lewis, M. C. (2005). Coantagonism of glutamate receptors and nicotinic acetylcholinergic receptors disrupts fear conditioning and latent inhibition of fear conditioning. Learning & Memory, 12, 389-398.
48. Grant, P. F., Hasin, D. S., Chou, S. P., Stinson, F. S., & Dawson, D. A. (2004). Nicotine dependence and psychiatric disorders in the United States. Archives of General Psychiatry, 61, 1107-1115.
49. Gray, N. S., Pickering, A. D., Hemsley, D. R., Dawling, S., & Gray, J. A. (1992). Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology (Berl.), 107, 425-430.
50. Gray, N. S., & Snowden, R. J. (2005). The relevance of irrelevance to schizophrenia. Neuroscience and Biobehavioral Reviews, 29, 989-999.
51. Halliwell, R. F. (2007). A short history of the rise of the molecular pharmacology of ionotropic drug receptors. Trends in Pharmacological Sciences, 28, 214-218.
52. Harvey, D. M., Yasar, S., Heishman, S. J., et al. (2004). Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl.), 175, 134-142.
53. Heishman, S. J. (1998). What aspects of human performance are truly enhanced by nicotine? Addiction, 93, 317-320.
54. Heishman, S. J., Snyder, F. R., & Henningfield, J. E. (1993). Performance, subjective, and physiological effects of nicotine in non-smokers. Drug and Alcohol Dependence, 34, 11-18.
55. Hitsman, B., Spring, B., Pingitore, R., Munafo, M., & Hedeker, D. (2007). Effect of tryptophan depletion on the attentional salience of smoking cues. Psychopharmacology (Berl.), 192, 317-324.
56. Holmes, A. D., Chenery, H. J., & Copland, D. A. (2008). Transdermal nicotine modulates strategy-based attentional semantic processing in non-smokers. Neuropsychopharmacology, 11, 389-399.
57. Hughes, J. R., Hatsukami, D. K., Mitchell, J. E., & Dahlgren, L. A. (1986). Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry, 143, 993-997.
58. Hunt, S. P., & Schmidt, J. (1978). The electron microscopic autoradiographic localization of a-bungarotoxin binding sites within the central nervous system. Brain Research, 142, 152-159.
59. Jackson, K. J., Martin, B. R., Changeux, J. P., & Damaj, M. I. (2008). Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotinic withdrawal signs. Journal of Pharmacology and Experimental Therapeutics, 325, 302-312.
60. Jacobsen, L. K., D'Souza, D. C., Mencl, W. E., et al. (2004). Nicotine effects on brain function and functional connectivity in schizophrenia. Biological Psychiatry, 55, 850-858.
61. James, W. (1890). Principles of Psychology. New York: Henry Holt.
62. Joseph, M. H., Datla, K., & Young, A. M. (2003). The interpretation of the measurement of nucleus accumbens dopamine by in vivo dialysis: the kick, the craving or the cognition? Neuroscience and Biobehavioral Reviews, 27, 527-541.
63. Joseph, M. H., Peters, S. L., & Gray, J. A. (1993). Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure. Psychopharmacology (Berl.), 110, 187-192.
64. Joseph, M. H., Peters, S. L., Moran, P.M., et al. (2000). Modulation of latent inhibition in the rat by altered dopamine transmission in the nucleus accumbens at the time of conditioning. Neuroscience, 101, 921-930.
65. Kalivas, P. W. (2007). Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity. Dialogues in Clinical Neuroscience, 9, 389-397.
66. Kalivas, P. W., Lalumiere, R. T., Knackstedt, L., & Shen, H. (2009). Glutamate transmission in addiction. Neuropharmacology, 56 (Suppl. 1), 169-173.
67. Kalivas, P. W., & O'Brien, C. (2008). Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology, 33, 166-180.
68. Kumari, V., Cotter, P. A., Mulligan, O. F., et al. (1999). Effects of d-amphetamine and haloperidol on latent inhibition in healthy male volunteers. Journal of Psychopharmacology, 13, 398-405.
69. Kumari, V., & Postma, P. (2005). Nicotine use in schizophrenia: the self medication hypotheses. Neuroscience and Biobehavioral Reviews, 29, 1021-1034.
70. Lalumiere, R. T., & Kalivas, P. W. (2008). Glutamate release in the nucleus accumbens core is necessary for heroin seeking. Journal of Neuroscience, 28, 3170-3177.
71. Lasser, K., Boyd, J. W., Woolhander, S., Himmelstein, D. A., & McCormick, D.M. (2000). Smoking and mental illness: a population-based prevalence study. Journal of the American Medical Association, 284, 2606-2610.
72. Leonard, S., Adler, L. E., Benhammou, K., et al. (2001). Smoking and mental illness. Pharmacology, Biochemistry and Behavior, 70, 561-570.
73. Levin, E. D., McClernon, F. J., & Rezvani, A. H. (2006). Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl.), 184, 523-539.
74. Levin, E. D., & Rezvani, A. H. (2006). Nicotinic-antipsychotic drug interactions and cognitive function. EXS, 98, 185-205.
75. Levin, E. D., & Rezvani, A. H. (2007). Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochemical Pharmacology, 74, 1182-1191.
76. Levin, E. D., Wilson, W., Rose, J. E., & McEvoy, J. (1996). Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology, 15, 429-436.
77. Liu, C. M., Chang, S. S., Liao, S. C., et al. (2007). Absent response to niacin skin patch is specific to schizophrenia and independent of smoking. Psychiatry Research, 152, 181-187.
78. Lubow, R., Schnur, P., & Rifkin, B. (1976). Latent inhibition and conditioned attention theory. Journal of Experimental Psychology. Animal Behavior Processes, 2, 163-174.
79. Lubow, R. E. (2005). Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophrenia Bulletin, 31, 139-153.
80. Luetje, C. W., & Patrick, J. (1991). Both a and b subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. Journal of Neuroscience, 11, 837-845.
81. Mackintosh, N. J. (1975). A theory of attention: variations in the associability of stimuli with reinforcement. Psychological Review, 82, 276-298.
82. Mansvelder, H. D., van Aerde, K. I., Couey, J. J., & Brussaard, A. B. (2006). Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacology (Berl.), 184, 292-305.
83. Mathew, S. V., Law, A. J., Lipska, B. K., et al. (2007). a7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic ariation in neuroregulin 1. Human Molecular Genetics, 16, 2921-2932.
84. Mihalak, K. B., Carroll, F. I., & Luetje, C.W. (2006). Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Molecular Pharmacology, 70, 801-805.
85. Miyazawa, A., Fujiyoshi, Y., & Unwin, N. (2003). Structure and gating mechanism of the acetylcholine receptor pore. Nature, 423, 949-955.
86. Myers, C. S., Taylor, R. C., Moolchan, E. T., & Heishman, S. J. (2008). Dose-related enhancement of mood and cognition in smokers administered nicotine nasal spray. Neuropsychopharmacology, 33, 588-598.
87. Nauright, L. P. (1987). Toward a comprehensive personnel system: the reward system-Part V. Nursing Management, 18, 58-4.
88. Nef, P., Oneyser, C., Alliod, C., Couturier, S., & Ballivet, M. (1998). Genes expressed in the brain define three distinct neuronal nicotinic acetylcholine receptors. The EMBO Journal, 7, 595-601.
89. Ochoa, E. L., & Lasalde-Dominicci, J. (2007). Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cellular and Molecular Neurobiology, 27, 609-639.
90. Olincy, A., Harris, J. G., Johnson, L. L., et al. (2006). Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Archives of General Psychiatry, 63, 630-638.
91. Orosz, A. T., Feldon, J., Gal, G., Simon, A. E., & Cattapan-Ludewig, K. (2008). Deficient associative learning in drug-naive first-episode schizophrenia: results obtained using a new visual within-subjects learned irrelevance paradigm. Behavioural Brain Research, 193, 101-107.
92. Palmatier, M. I., Liu, X., Caggiula, A. R., Donny, E. C., & Sved, A. F. (2007). The role of nicotinic acetylcholine receptors in the primary reinforcing and reinforcement-enhancing effects of nicotine. Neuropsychopharmacology, 32, 1098-1108.
93. Patkar, A. A., Gopalakrishnan, R., Lundy, A., et al. (2002). Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. Journal of Nervous and Mental Disease, 190, 604-610.
94. Postma, P., Gray, J. A., Sharma, T., et al. (2006). A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia. Psychopharmacology (Berl.), 184, 589-599.
95. Rascle, C., Mazas, O., Vaiva, G., et al. (2001). Clinical features of latent inhibition in schizophrenia. Schizophrenia Research, 51, 149-161.
96. Rezvani, A. H., Caldwell, D. P., & Levin, E. D. (2005). Nicotinic-serotonergic drug interactions and attentional performance in rats. Psychopharmacology (Berl.), 179, 521-528.
97. Rezvani, A. H., & Levin, E. D. (2003). Nicotinic-glutamatergic interactions and attentional performance on an operant visual signal detection task in female rats. European Journal of Pharmacology, 465, 83-90.
98. Rezvani, A. H., & Levin, E. D. (2004). Nicotine-antipsychotic drug interactions and attentional performance in female rats. European Journal of Pharmacology, 486, 175-182.
99. Rezvani, A. H., Tizabi, Y., Getachew, B., et al. (2008). Chronic nicotine and dizocilpine effects on nicotinic and NMDA glutamatergic receptor regulation: interactions with clozapine actions and attentional performance in rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32, 1030-1040.
100. Robbins, T. W. (2002). The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl.), 163, 362-380.
101. Robinson, T. E., & Berridge, K. C. (2000). The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction, 95 Suppl 2, S91-117.
102. Rochford, J., Sen, A. P., Rousse, I., & Welner, S. A. (1996). The effect of quisqualic acid-induced lesions of the nucleus basalis magnocellularis on latent inhibition. Brain Research Bulletin, 41, 313-317.
103. Ruob, C., Elsner, J., Weiner, I., & Feldon, J. (1997). Amphetamine-induced disruption and haloperidol-induced potentiation of latent inhibition depend on the nature of the stimulus. Behavioural Brain Research, 88, 35-41.
104. Ruob, C., Weiner, I., & Feldon, J. (1998). Haloperidol-induced potentiation of latent inhibition: interaction with parameters of conditioning. Behavioural Pharmacology, 9, 245-253.
105. Rycroft, N., Rusted, J.M., & Hutton, S. B. (2005). Acute effects of nicotine on visual search tasks in young adult smokers. Psychopharmacology (Berl.), 181, 169.
106. Sacco, K. A., Bannon, K. L., & George, T. P. (2004). Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. Journal of Psychopharmacology, 18, 457-474.
107. Sacco, K. A., Termine, A., Seyal, A., et al. (2005). Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Archives of General Psychiatry, 62, 649-659.
108. Salas, R., Main, A., Gangitano, D., & De, B. M. (2007). Decreased withdrawal symptoms but normal tolerance to nicotine in mice null for the alpha7 nicotinic acetylcholine receptor subunit. Neuropharmacology, 53, 863-869.
109. Salvaterra, P. M., & Mahler, H. R. (1976). Nicotinic acetylcholine receptor from rat brain. Journal of Biological Chemistry, 25, 6327-6334.
110. Schmajuk, N. A., Buhusi, C. V., & Gray, J. A. (1998). Psychopharmacology of latent inhibition: a neural network approach. Behavioural Pharmacology, 9, 711-730.
111. Schultz, W., Dayan, P., & Montague, P. R. (1997). A neural substrate of prediction and reward. Science, 275, 1593-1599.
112. Semenova, S., Stolerman, I. P., & Markou, A. (2007). Chronic nicotine administration improves attention while nicotine withdrawal induces performance deficits in the 5-choice serial reaction time task in rats. Pharmacology, Biochemistry and Behavior, 87, 360-368.
113. Severance, E. G., & Yolken, R. H. (2008). Novel a7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia. Genes, Brain, and Behavior, 7, 37-45.
114. Smith, R. C., Singh, A., Infante, M., Khandat, A., & Kloos, A. (2002). Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology, 27, 479-497.
115. Smith, R. C., Warner-Cohen, J., Matute, M., et al. (2006). Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology, 31, 637-643.
116. Solomon, P. R., Crider, A., Winkelman, J. W., et al. (1981). Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder. Biological Psychiatry, 16, 519-537.
117. Swerdlow, N. R., Stephany, N., Wasserman, L. C., et al. (2003). Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. Psychopharmacology (Berl.), 169, 314-320.
118. Terry, A. V., Risbrough, V. B., Buccafusco, J. J., & Menzaghi, F. (2002). Effects of (þ/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. Journal of Pharmacology and Experimental Therapeutics, 301, 284-292.
119. Thornton, J. C., Dawe, S., Lee, C., et al. (1996). Effects of nicotine and amphetamine on latent inhibition in human subjects. Psychopharmacology (Berl.), 127, 164-173.
120. Torregrossa, M. M., & Kalivas, P.W. (2008). Microdialysis and the neurochemistry of addiction. Pharmacology, Biochemistry and Behavior, 90, 261-272.
121. Tribollet, E., Marguerat, A., & Raggenbass, M. (2004). Comparative distribution of nicotinic receptor subtypes during development, adulthood and aging: an autoradiographic study in the rat brain. Neuroscience, 12, 405-420.
122. Vaitl, D., Lipp, O., Bauer, U., et al. (2002). Latent inhibition and schizophrenia: Pavlovian conditioning of autonomic responses. Schizophrenia Research, 55, 147-158.
123. Valenstein, E. S. (2002). The discovery of chemical transmitters. Brain and Cognition, 49, 73-95.
124. Volkow, N. D., Fowler, J. S., & Wang, G. J. (2002). Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behavioural Pharmacology, 13, 355-366.
125. Wada, K., Ballivet, M., Boulter, J., et al. (1988). Functional expression of a new pharmacological subtype of brain nicotinic acetylcholine receptor. Science, 240, 330-334.
126. Walters, C. L., Brown, S., Changeux, J. P., Martin, B., & Damaj, M. I. (2006). The beta2 but not alpha7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice. Psychopharmacology (Berl.), 184, 339-344.
127. Weiner, I. (1990). Neural substrates of latent inhibition: the switching model. Psychological Bulletin, 108, 442-461.
128. Weiner, I., & Feldon, J. (1987). Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology (Berl.), 91, 248-253.
129. Weiner, I., Lubow, R. E., & Feldon, J. (1981). Chronic amphetamine and latent inhibition. Behavioural Brain Research, 2, 285-286.
130. Weiner, I., Lubow, R. E., & Feldon, J. (1984). Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology (Berl.), 83, 194-199.
131. Weiner, I., Lubow, R. E., & Feldon, J. (1988). Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacology, Biochemistry and Behavior, 30, 871-878.
132. Weiner, I., Shadach, E., Tarrasch, R., Kidron, R., & Feldon, J. (1996). The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine. Biological Psychiatry, 40, 834-843.
133. Williams, J. H., Wellman, N. A., Geaney, D. P., et al. (1996). Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people. Biological Psychiatry, 40, 1135-1143.
134. Williams, J. H., Wellman, N. A., Geaney, D. P., et al. (1997). Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology (Berl.), 133, 262-268.
135. Wise, R. A. (2004). Dopamine, learning and motivation. Nature Reviews. Neuroscience, 5, 483-494.
136. Yang, Y. K., Nelson, L., Kamaraju, L., Wilson, W., & McEvoy, J. P. (2002). Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. Neuropsychopharmacology, 27, 684-686.
137. Young, A.M., Kumari, V., Mehrotra, R., et al. (2005). Disruption of learned irrelevance in acute schizophrenia in a novel continuous within-subject paradigm suitable for fMRI. Behavioural Brain Research, 156, 277-288.